Article Text
Research ethics
Can artificial parthenogenesis sidestep ethical pitfalls in human therapeutic cloning? An historical perspective
Abstract
The aim of regenerative medicine is to reconstruct tissue that has been lost or pathologically altered. Therapeutic cloning seems to offer a method of achieving this aim; however, the ethical debate surrounding human therapeutic cloning is highly controversial. Artificial parthenogenesis—obtaining embryos from unfertilised eggs—seems to offer a way to sidestep these ethical pitfalls. Jacques Loeb (1859–1924), the founding father of artificial parthogenesis, faced negative public opinion when he published his research in 1899. His research, the public’s response to his findings, and his ethical foundations serve as an historical argument both for the communication of science and compromise in biological research.
- artificial parthenogenesis
- therapeutic cloning
- regenerative medicine
- ethics
- history
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Human embryonic stem cell research debates: a Confucian argument
- The significance of induced pluripotent stem cells for basic research and clinical therapy
- Regenerative medicine: stem cells and the science of monstrosity
- What happened to the stem cells?
- Is a consensus possible on stem cell research? Moral and political obstacles
- Adam’s fibroblast? The (pluri)potential of iPCs
- Time to reconsider stem cell ethics—the importance of induced pluripotent cells
- Artificial gametes: new paths to parenthood?
- Stem cells as a resource for regenerative neurology
- Stem cells, embryos, and the environment: a context for both science and ethics